Apogee Therapeutics Inc
APGE
Company Profile
Business description
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.
Contact
221 Crescent Street
Building 17, Suite 102b
WalthamMA02453
USAT: +1 650 394-5230
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
196
Stocks News & Analysis
stocks
Our top ASX picks in every sector
These companies are our top choices for investors wanting to boost Aussie exposure.
stocks
Potentially catastrophic ruling for ASX company
We raise our risk and uncertainty rating to reflect the impact of the ruling.
stocks
4 charts on Nvidia’s record $4 trillion market cap
Shares of the semiconductor giant have rocketed 280% over the past two years amid the AI boom.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,852.20 | 36.90 | 0.42% |
| CAC 40 | 7,808.17 | 21.12 | -0.27% |
| DAX 40 | 24,160.64 | 94.67 | -0.39% |
| Dow JONES (US) | 44,459.65 | 88.14 | 0.20% |
| FTSE 100 | 8,998.06 | 56.94 | 0.64% |
| HKSE | 24,250.90 | 47.58 | 0.20% |
| NASDAQ | 20,640.33 | 54.80 | 0.27% |
| Nikkei 225 | 39,513.46 | 53.84 | 0.14% |
| NZX 50 Index | 12,691.00 | 12.31 | 0.10% |
| S&P 500 | 6,268.56 | 8.81 | 0.14% |
| S&P/ASX 200 | 8,609.20 | 38.80 | 0.45% |
| SSE Composite Index | 3,486.88 | 32.77 | -0.93% |